Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · IEX Real-Time Price · USD
-0.015 (-5.12%)
At close: Apr 19, 2024, 4:00 PM
+0.002 (0.75%)
After-hours: Apr 19, 2024, 6:13 PM EDT

Company Description

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States.

It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.

The company's product candidates include Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms, as part of menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia, or pain during sexual intercourse; and DARE-CIN for cervical intraepithelial neoplasia and other human papillomavirus related pathologies treatment.

It is also developing DARE-PDM1 to treat primary dysmenorrhea; DARE-204 and DARE-214 that provides contraception over 6-month and 12-month periods, respectively; DARE-FRT1 for luteal phase support as part of an in vitro fertilization treatment plan; DARE-PTB1 for the prevention of preterm birth; DARE-LARC1, a contraceptive implant; DARE-LBT for vaginal health support; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein.

The company also offers XACIATO, for the treatment of bacterial vaginosis in female patients 12 years of age and older.

It has a license agreement with Organon & Co., Organon International GmbH, Bayer, Douglas Pharmaceuticals Limited, and Hennepin Life Sciences LLC.

Daré Bioscience, Inc. is headquartered in San Diego, California.

Daré Bioscience, Inc.
Daré Bioscience logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Ms. Sabrina Martucci Johnson

Contact Details

3655 Nobel Drive, Suite 260
San Diego, California 92122
United States
Phone 858-926-7655
Website darebioscience.com

Stock Details

Ticker Symbol DARE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001401914
CUSIP Number 23666P101
ISIN Number US23666P1012
Employer ID 20-4139823
SIC Code 2834

Key Executives

Name Position
Sabrina Martucci Johnson Chief Executive Officer, President, Principal Financial Officer, Secretary and Director
Lisa Walters-Hoffert Executive Officer
Mark Walters Vice President of Operations
MarDee J. Haring-Layton Chief Accounting Officer
Dr. David Friend Chief Scientific Officer

Latest SEC Filings

Date Type Title
Apr 16, 2024 PRE 14A Other preliminary proxy statements
Mar 29, 2024 S-3 Registration statement under Securities Act of 1933
Mar 29, 2024 S-3 Registration statement under Securities Act of 1933
Mar 28, 2024 424B5 Filing
Mar 28, 2024 10-K Annual Report
Mar 28, 2024 8-K Current Report
Jan 26, 2024 8-K Current Report
Jan 19, 2024 8-K Current Report
Jan 8, 2024 8-K Current Report
Dec 26, 2023 D Notice of Exempt Offering of Securities